Adicet Bio

Adicet Bio EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio (ACET) as of Oct 17, 2026 is -63.48 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -57.95 % — a change of 9.55% (lower).

EBIT/Assets

-63.48 %

YoY

9.55%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio is 2025 -63.48 % . Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio was 2024 -57.95 % . It decreases by 9.55% lower compared to the previous year.

The Adicet Bio EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-13.61 USD
Jan 1, 2019
-38.47 USD
Jan 1, 2020
-25.48 USD
Jan 1, 2021
-18.30 USD
Jan 1, 2022
-21.94 USD
Jan 1, 2023
-73.34 USD
Jan 1, 2024
-57.95 USD
Jan 1, 2025
-63.48 USD
The Adicet Bio EBIT/Assets history
YEAREBIT/AssetsYoY
-63.48 %+9.55%
-57.95 %-20.99%
-73.34 %+234.30%
-21.94 %+19.86%
-18.30 %-28.15%
-25.48 %-33.78%
-38.47 %+182.65%
-13.61 %-60.21%
-34.21 %+18.50 M%
-0.00-100.00%
9.04 %+22.91%
7.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adicet Bio Stock analysis

What does Adicet Bio do? Adicet Bio Inc, headquartered in Boston, Massachusetts, is a biotechnology company focused on developing off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company, listed on 26 January 2018, employs 102 full-time staff and is advancing a pipeline of engineered gamma delta T cell therapies, including ADI-001 targeting CD20 and ADI-002 targeting GPC3, designed to enable selective tumor targeting and durable anti-tumor responses. Adicet Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adicet Bio stock

Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio is -63.48 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Adicet Bio changed from -57.95 % to -63.48 %, representing a 9.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Adicet Bio since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Adicet Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Adicet Bio

All Key Metrics — Adicet Bio